ORIGINAL RESEARCH ARTICLE ORIGINAL RESEARCH ARTICLE BACKGROUND: In infants requiring 3-stage single-ventricle palliation for hypoplastic left heart syndrome, attrition after the Norwood procedure remains significant. The effect of the timing of stage 2 palliation (S2P), a physician-modifiable factor, on long-term survival is not well understood. We hypothesized that an optimal interval between the Norwood and S2P that both minimizes pre-S2P attrition and maximizes post-S2P survival exists and is associated with individual patient characteristics.
I
n infants with hypoplastic left heart syndrome requiring 3-stage single-ventricle palliation, mortality between the Norwood procedure and stage 2 palliation (S2P) remains high, ranging from 2% to 20%. In the SVR trial (Single Ventricle Reconstruction), 16% died before Norwood hospitalization discharge and another 12% died after discharge and before S2P. [1] [2] [3] The National Pediatric Cardiology Quality Improvement Collaborative recently reported similar 10% postdischarge mortality after the Norwood hospitalization before S2P. [4] [5] [6] It remains unknown whether shortening an infant's exposure to Norwood-associated cardiovascular physiology would decrease pre-S2P attrition. The parallel circulation present after initial palliation requires the single ventricle to perform excess volume work and may expose the pulmonary vasculature to elevated pressures. Progression to S2P eliminates the risk of systemic to pulmonary artery shunt failure, greatly reduces the excess volume work performed by the ventricle, normalizes coronary arterial diastolic blood pressure in patients with a modified Blalock-Taussig shunt (MBTS), and reduces pulmonary overcirculation. However, very early conversion to S2P is not without risk, including potentially reduced pulmonary arterial growth, pulmonary vascular resistance higher than desirable for S2P, and increased resource use in younger patients. 7 The current evidence regarding the timing of S2P is limited to single-institution studies that only report outcomes after S2P, without accounting for pre-S2P mortality. Two decades ago, small case series focused on how early S2P can be performed with acceptable outcomes. [8] [9] [10] [11] Recent studies have yielded contradictory conclusions, regardless of how timing was analyzed. [12] [13] [14] [15] [16] Secondary analyses of the SVR and Infant Single Ventricle trials showed no association of age at S2P with survival, hypoxemia, or ejection fraction. 17, 18 The timing of S2P remains at the discretion of institutional or individual surgeon/cardiologist preferences.
The primary objectives of this study were to investigate the clinical factors associated with the timing of S2P and to determine the optimal timing of S2P that both minimizes pre-S2P attrition and maximizes post-S2P survival.
METHODS

Study Design
The National Institutes of Health/National Heart, Lung, and Blood Institute Pediatric Heart Network SVR trial data set was used in preparation of this work. Data collected at enrollment through 3-year follow-up were downloaded from the Pediatric Heart Network 19 on August 6, 2015. The SVR trial was a prospective, multicenter, randomized, controlled trial comparing 1-year transplant-free survival in patients undergoing the Norwood procedure, randomly assigned to receive a MBTS or a right ventricular-to-pulmonary artery (RVPA) conduit, with ongoing long-term follow-up. The details of recruitment, inclusion and exclusion, patient management, and data collection have been previously reported. 20, 21 The study protocol was approved by each participating site's institutional review board. Before randomization, each patient's parent or guardian provided written informed consent. The pre-Norwood medical history, Norwood procedure and postoperative course, S2P operation and postoperative course, postnatal echocardiograms (pre-Norwood, post-Norwood, and pre-S2P), pre-S2P angiography and cardiac catheterization, and 3-year outcomes were analyzed. Shunt type was defined as the shunt in place at the end of the Norwood hospitalization. No data regarding Fontan completion were available in the public data set.
Study Population
Of the 549 patients who were included in the original analysis of the trial's primary end point, 547 were included in this study. Two patients were excluded: one who underwent S2P but had no operative data available, and one who had an excessively long Norwood-S2P interval (22.8 months).
Clinical Perspective
What Is New?
• Mortality in infants with hypoplastic left heart syndrome undergoing single-ventricle palliation remains high, especially prior to stage 2 palliation (S2P).
• The effect of the timing of the S2P, a physicianmodifiable factor, is not well understood.
• In low-or average-risk infants, S2P between 3 and 6 months post-Norwood was associated with maximal 3-year transplant-free survival.
• Optimal timing of S2P did not differ between patients who had Blalock-Taussig shunts or right ventricle-to-pulmonary artery conduits.
• Identifiable characteristics exist that severely compromise 3-year transplant-free survival, irrespective of timing of S2P or shunt type.
What Are the Clinical Implications?
• Adoption of formal clinical protocols to ensure that operative planning for S2P in infants with few risk factors occurs before discharge after the Norwood procedure may lead to improved outcomes.
• In infants in whom 3-stage single-ventricle palliation has a high risk of failure, the practice of proceeding rapidly to S2P after the Norwood incurs a major survival cost.
• Although organ donor supply is severely limited, early cardiac transplantation may provide these high-risk infants with their greatest chance at longterm survival.
Clinical and Operative Data
The baseline characteristics, operative details, and outcomes of the Norwood procedure and S2P in the SVR trial participants have been reported previously. 5, 18, 21, 22 The majority of patients underwent a right bidirectional superior cavopulmonary connection or a right hemi-Fontan operation. The elective status of the S2P operation was coded as elective or nonelective, at the discretion of each site investigator. 18 Specific indications for nonelective S2P were coded as progressive hypoxemia, failure to thrive, shunt occlusion, neoaortic arch obstruction, moderate or greater systemic atrioventricular valvular insufficiency, ventricular dysfunction, or other, again at the discretion of the site investigators.
Statistical Analysis
Survival Analysis and Multivariable Modeling
Time-related analyses of the primary outcome, a composite of death or heart transplantation, were performed over 2 intervals, after the Norwood and after S2P (online-only Data Supplement Figure I ). Transplant-free survival was modeled for both intervals using parametric risk hazard analysis. In brief, parametric hazard analysis models the hazard function by decomposing it into multiple phases of risk. Three phases of risk may exist, although they are not required for model validity (an early peaking, rapidly decreasing hazard, a constant phase, and late, rising hazard). The SAS procedure PROC HAZARD uses the maximum likelihood method to resolve the phases of the distribution of times until an event. 23 Additional details can be found at the Lerner Research Institute.
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Multivariable risk hazard analysis was performed to identify factors associated with death or heart transplantation after each operation. Bootstrap aggregation, or sampling with replacement (n=500 resamples), was used to guide variable selection. 25 The final model was built using forward stepwise selection, with P<0.07 for entry and P<0.05 for retention. Variables with >50% missing values were excluded. For variables with <50% missing data, multiple informative imputation using PROC MI was performed. To graphically depict the effects of risk factors on survival, representative curves were generated in which values for the risk factors were specified in the multivariable models. Specifically, the multivariable parametric equations were solved for specified values of the associated factors. Summary or average curves were created by generating predicted survival curves for each individual study patient, using their actual values for the factors in the multivariable equations, and then summarized into a single curve.
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Determinants of Timing of S2P
Linear regression, in which the outcome was the length of the Norwood-S2P interval, was used to determine the patient characteristics significantly associated with the timing of S2P. Bootstrap aggregation was used to aid in variable selection (n=500 resamples), and covariables with >50% reliability were included for final selection (stepwise selection, P=0.07 for entry, P=0.05 for retention).
Analysis of the Timing of S2P
Locally weighted scatterplot smoothing logistic regression was first used to model the relationship between the timing of S2P and transplant-free survival after S2P in patients who survived to S2P. Parametric conditional survival analysis was used to analyze survival through the Norwood and S2P. Conditional survival is defined as the probability of surviving to time t given survival to time s [CS(t|s)], or the probability of surviving to 3 years after the Norwood procedure given survival to S2P. 27, 28 Transplant-free survival after the Norwood procedure to the day of S2P was predicted using the parametric model for transplant-free survival after the Norwood, as described above. The model for transplant-free survival after S2P was next used to predict transplant-free survival to 3 years, which was then adjusted for attrition before S2P by multiplying by the estimated transplant-free survival to the day of S2P obtained from the first model. The optimal timing was determined by creating nomograms in which the predicted 3-year, post-Norwood, transplantfree survival was plotted as a function of the Norwood-S2P interval. Detailed information regarding analytic techniques can be found in the online-only Data Supplement Materials and online-only Data Supplement Figures II through VII. All statistical analyses were performed using SAS version 9.2 (SAS Institutes).
RESULTS
Patient Outcomes and Risk Factors Before S2P
Of the 547 patients who underwent a Norwood procedure, 139 (25%) died and 9 (2%) underwent cardiac transplantation. Factors associated with death or transplant after Norwood included MBTS versus RVPA conduit, requiring extracorporeal membrane oxygenation (ECMO) at the end of the Norwood, the use of steroids during the Norwood, smaller pre-Norwood tricuspid valve diameter z score, the presence of an aberrant right subclavian artery, the use of aprotinin during the Norwood, site volume ≤30 Norwood procedures per year, longer cardiopulmonary bypass time, longer deep hypothermic circulatory arrest time, and higher pre-Norwood lactate value (Table 1) .
Of the remainder, 399 (73%) underwent S2P. Factors associated with reaching S2P included a smaller percentage below the federal poverty line, shorter deep hypothermic circulatory arrest time, performing a coarctectomy during the Norwood procedure, and smaller pre-Norwood tricuspid valve diameter z score (Table 1) .
Patient Outcomes and Risk Factors After S2P
Of the 399 who underwent S2P, 349 (87%) survived to 3-year follow-up, 39 (10%) died, and 11 (3%) underwent cardiac transplantation. The median interval between the day of the Norwood and the day of S2P was 5.1 (interquartile range, 4.1-6.0) months. Among the 399 patients who underwent S2P, 66% were elective operations. Parametric risk hazard analysis resolved 2 phases of risk after S2P, an early and a constant phase. Factors associated with death or transplant during the early phase included smaller neoaortic annular area z score on the post-Norwood echocardiogram, the presence of pulmonary artery stenosis before S2P, greater number of post-Norwood complications, failure to thrive as an indication for S2P, severe systemic atrioventricular valve regurgitation, and requiring ECMO after the Norwood. Specifically, a shorter interval between the Norwood procedure and S2P was associated with an increased risk of death or heart transplantation. The only significant associated factor during the constant phase was a lower right ventricular ejection fraction on the pre-S2P echocardiogram (Table 2) .
Risk-Adjusted, Transplant-Free Survival at 3 Years
Overall, the unadjusted, transplant-free survival at 3 years post-Norwood was 63±2%. Using the actual values for the factors associated with death or heart transplantation, the risk-adjusted, 3-year, post-Norwood, transplant-free survival through both the Norwood procedure and S2P for all 547 infants was 68±7% (Figure 1 ).
Determinants of the Timing of S2P
The interval from the Norwood to S2P was modeled and the results are shown in Table 3 . Covariables associated with a shorter interval included shunt stenosis at the time of S2P, ventricular dysfunction as an indication for S2P, the use of intraoperative α-blockade, center volume of ≤20 Norwood procedures per year, male sex, and a higher weight-for-age z score at the pre-S2P catheterization. Covariables associated with a longer interval included smaller left pulmonary artery diameter on the pre-S2P catheterization, a greater right ventricular end-diastolic volume on the pre-S2P echocardiogram, a greater total number of operations during the interstage period, the use of aprotinin during the Norwood, the use of steroids during the Norwood, and electively performed S2P.
The Optimal Timing of S2P in the SVR Trial
Exploratory analysis using locally weighted scatterplot smoothing regression demonstrated that the probability of death or heart transplantation was initially just Using the parametric models for transplant-free survival after the Norwood and after stage 2 palliation, curves representing transplant-free survival were calculated for all 547 patients in the trial, using their actual risk factor values. All curves were then averaged into a single curve, which is displayed here. The risk-adjusted, transplant-free survival at 3 years was 68±7%. The dashed lines represent the 70% confidence limits. Figure VIII) . It then decreased as the Norwood-S2P interval lengthened and rose again to ≈20% as the interval approached 13 months.
>20% (online-only Data Supplement
The optimal timing of S2P was then determined by plotting calculated 3-year, risk-adjusted, post-Norwood transplant-free survival versus the Norwood-S2P interval. Using the actual patient values for all 547 patients in both multivariable models, an averaged nomogram was created and is shown in Figure 2 . Calculated transplant-free survival at 3 years was stable at 68±7% during a Norwood-S2P interval of 3 to 6 months. Calculated transplant-free survival decreased rapidly when S2P was performed before 3 months after the Norwood and then again, although more gradually, after 6 months.
The Effect of Performing S2P Outside the Optimal Timing
The effect of performing S2P outside the optimal window on transplant-free survival can be demonstrated by plotting survival over time, stratified by day of S2P. In online-only Data Supplement Figure IXA , transplantfree survival was calculated at 3 years after the Norwood procedure and was stratified by the day of S2P for a hypothetical average patient (all associated factor values in the multivariable models were set at their mean values). Performing S2P before 1.5 (red curve) or 2 (pink curve) months after the Norwood resulted in 3-year transplant-free survival estimates of 63±11% and 69±6%, respectively. Calculated 3-year transplantfree survival estimates when S2P was performed at 3 (orange curve), 4 (yellow curve), and 5 (green curve) months after the Norwood were 73±3%, 73±3%, and 73±3%, respectively (online-only Data Supplement Figure IXB) . Steady decrements in calculated transplant-free survival was seen when S2P was performed after Norwood-S2P intervals >6 months, with 3-year transplant-free survival estimates of 73±3%, 72±3%, 71±4%, 69±4%, and 65±4% when S2P was performed at 6 (blue curve), 7 (purple curve), 8 (brown curve), 9 (gray curve), or 12 (black curve) months, respectively (online-only Data Supplement Figure IXC 
The Effect of Specific Risk Factors on the Timing of S2P
The nomograms depicting calculated risk-adjusted transplant-free survival can be stratified by a selected associated factor from the multivariable models. In this manner, the effect of shunt type at the end of the Norwood hospitalization was investigated. Figure 3A demonstrates that the optimal timing of S2P does not differ by shunt type, because the confidence limits of each curve overlap for any Norwood-S2P interval. Therefore, the same Norwood-S2P interval of 3 to 6 is associated with maximal calculated transplant-free survival in patients regardless of shunt type. Similarly, the interval associated with maximal calculated 3-year, transplantfree survival in patients with failure to thrive was investigated. In Figure 3B , undergoing S2P before 6 months after the Norwood procedure resulted in calculated a 3-year, transplant-free survival <50%.
The Optimal Timing of S2P Based on Individual Patient Risk Profiles
In Figure 4 , curves solved using the actual values for the associated factors for individual patients with few and multiple risk factors are shown, along with the averaged curve for all patients in the study cohort. When comparing a patient with few risk factors (blue curve) with the cohort average (black curve), there was no difference in the Norwood-S2P interval that was associated with maximal calculated 3-year, transplant-free survival. However, in a patient with multi- ple risk factors (orange curve), performing S2P before a Norwood-S2P interval of 6 months was associated with calculated a 3-year, transplant-free survival of <50% ( Figure 4 ).
DISCUSSION
We investigated the optimal timing of S2P associated with minimal post-Norwood attrition and maximal post-S2P survival. A shorter Norwood-S2P interval was associated with an increased risk for death or heart transplantation after S2P. In low-or average-risk patients, an interval of 3 to 6 months after the Norwood was associated with maximal calculated transplant-free survival at 3 years post-Norwood. In high-risk patients, 3-year transplant-free survival was substantially compromised, regardless of the timing of S2P or shunt type. Patients with high-risk characteristics before the Norwood who required early progression to S2P demonstrated especially dismal outcomes.
Accounting for Transplant-Free Survival Through Staged Procedures
We used parametric conditional survival analysis to account for staged procedures. The nonparametric or semiparametric forms, based on Kaplan-Meier or Cox methods, have been increasingly applied in oncology over the past decade. [29] [30] [31] They have been used to predict survival beyond a given earlier time point, eg, survival to 5 years, given survival to 1 year after cancer resection. Survival after heart transplantation for congenital heart disease has been examined by using conditional survival analysis. 32, 33 In contrast, single-ventricle palliation requires multiple operations. Previous studies have analyzed survival after S2P only. Nonparametric conditional survival analysis was inadequate for this study, because it can only graphically display survival following the conditional event (ie, S2P), and thereby fails to provide important clinical information regarding the risk of significant attrition before S2P. Using a novel application of this method, we were able to more completely describe transplant-free survival from the Norwood procedure, through S2P, and up to 3-year follow-up.
The Optimal Timing of S2P in Patients Without Risk Factors
Since 2000, several single-center series have examined the timing of S2P, although many were limited by sample size and lack of risk adjustment. Jaquiss et al 12, 13 examined early and late outcomes in patients who underwent S2P either before or after 4 months of age, and found no difference in survival or Fontan completion. However, resource use was higher in the early S2P group. Petrucci et al 15 also reported equivalent survival between patients who underwent S2P before and after 3 months of age. Two studies determined that an age of <3 months at S2P was associated with an increased risk for death, heart transplantation, or inability to proceed with Fontan completion. 34, 35 Many other recent In this nomogram, the probability of transplant-free survival at 3 years after the Norwood procedure is plotted versus the interval between the Norwood and stage 2 palliation operations in months (solid line). Calculated transplant-free survival is severely compromised until after 3 months, at which it stabilizes at 68±7%, and begins to decrease again after 6 months. This curve was generated by producing nomograms for all 547 patients in the trial and averaging them into a single curve. The dashed lines represent the 70% confidence limits. S2P indicates stage 2 palliation.
ORIGINAL RESEARCH ARTICLE studies of the outcomes after S2P have not found the timing of S2P to be associated with outcomes. 14, 16, 36, 37 It is noteworthy that risk factors for death or heart transplantation after S2P have not yet been reported in SVR trial study participants. Schwartz et al 18 instead reported risk factors for prolonged hospital length of stay after S2P. Although many were similar to those described in this analysis, neither age at S2P nor the Norwood-S2P interval were identified.
Our results indicate that S2P performed between 3 and 6 months after the Norwood is associated with maximal calculated 3-year survival. Although the majority of patients who underwent elective S2P did actually undergo the operation within the 3-to 6-month window, 30 patients underwent S2P before 3 months after the Norwood and 52 underwent S2P after 6 months ( Figure 5A ). Four of the 30 patients underwent elective S2P at <3 months after the Norwood. It is unclear what prompted early progression to S2P among these patients. These may also simply represent coding errors for their indications for S2P. Of perhaps greater interest are the 14 patients who underwent nonelective progression to S2P after a Norwood-S2P interval of >6 months. Even though a single death occurred in these patients, this death may have been avoided, without harming these patients' chance of 3-year survival, by performing S2P electively before 6 months ( Figure 5B) . Alternatively, the true clinical reasons for the delay of S2P may not have been adequately captured in the SVR trial data set. In this case, although exhaustively performed in this analysis, incomplete risk adjustment may have occurred. Furthermore, the possibility exists that the factors identified may differentially affect the risk of death or heart transplantation in patients who undergo S2P earlier and later than the 3-to 6-month window.
Transplant-Free Survival Over Time When S2P Is Performed Outside the Optimal Timing
Parametric conditional survival analysis also enabled us to examine the effect of performing S2P outside the optimal timing, via the graphical depiction of calculated survival through several hypothetical times for S2P. These plots clearly demonstrate the much higher hazard for death and heart transplantation before S2P than after S2P (online-only Data Supplement Figures  IXA through IXC) . However, the hazard for death or transplant after S2P changes with the time at which S2P is performed. The nonlinear association between the timing of S2P and 3-year transplant-free survival is displayed. Performing S2P 1.5 months after the Norwood yields calculated survival estimates much closer to performing it at 12 months post-Norwood versus at 3 months. This family of curves demonstrates the clinical paradox: how to balance the risk of early S2P with the continuing attrition in the post-Norwood period.
The Optimal Timing of S2P Does Not Differ for Average-Risk Patients by Shunt Type
The goal of the SVR trial was to compare transplantfree survival at 1 year in patients who underwent the Norwood procedure randomly assigned to receive either a MBTS or RVPA conduit. In this analysis, we compared the timing of S2P associated with maximal calculated transplant-free survival. Although a MBTS was associated with death or heart transplant before S2P, the optimal interval did not differ between shunt types. No Norwood-S2P is associated with differential calculated, risk-adjusted, transplant-free survival whether the patients had a modified Blalock-Taussig shunt (MBTS) or a right ventricle-to-pulmonary artery (RVPA) conduit. This curve was generated by generating nomograms for all 547 patients in the trial, then averaging them into a single curve, and stratifying by shunt type at the end of the Norwood hospitalization. B, The optimal timing of S2P, stratified by the presence of failure to thrive (FTT) as an indication for progression to S2P. Performing S2P earlier than 6 months after the Norwood in patients with failure to thrive is associated with calculated risk-adjusted, transplant-free survival of <50%. This curve was generated by producing nomograms for all 547 patients in the trial, then averaging them into a single curve, and stratifying by failure to thrive. The dashed lines represent the 70% confidence limits.
A single study has described a difference in the timing of S2P based on shunt type. Rüffer and colleagues 38 noted greater survival in patients with an RVPA conduit until 4 months of age and that, after 4 months, the risk of death increased markedly at their institution. Therefore, they advocated catheterization at 2 months postNorwood and progression to S2P by 4 months. This was a single-institution study that only included 58 patients, and was analyzed nonparametrically and without risk adjustment. Although our analysis is in accordance with their recommendation of performing S2P at 4 months in patients with RVPA conduits, our data do not support their conclusion that patients require distinct timing of S2P based on shunt type.
S2P Does Not Rescue Patients With Risk Factors
Three-year transplant-free survival was substantially decreased in high-risk patients undergoing S2P. Calculated transplant-free survival was often <50% when S2P was performed before 6 months post-Norwood. This survival cost was especially striking when high-risk patients (in whom survival after the Norwood was already compromised) required S2P at a Norwood-S2P interval of <3 months, indicating that the early S2P does not rescue ill patients in the post-Norwood period.
It is tempting to conclude that delaying S2P in patients with significant risk factor burden would maxi- In low-risk patients (blue line), the optimal timing of S2P that maximizes calculated risk-adjusted, transplant-free survival at 3 years after the Norwood does not differ from the cohort average (black line, generated using all 547 patients, averaged into a single curve). In high-risk patients (orange line), earlier S2P is associated with much lower calculated risk-adjusted, transplant-free survival, ≤50%.
Risk factor values, patient with few risk factors: Did not require extracorporeal membrane oxygenation at the end of the Norwood procedure, modified Blalock-Taussig shunt, received steroids, pre-Norwood tricuspid valve z score=4.3, no aberrant right subclavian artery, received aprotinin, site volume <30 Norwood procedures per year, cardiopulmonary bypass time=111 minutes, highest pre-Norwood lactate=4.0 mg/dL, deep hypothermic circulatory arrest time=0 minutes, post-Norwood neoaortic annular area z score=10.85, no pulmonary arterial stenosis, 3 post-Norwood complications, no diagnosis of failure to thrive, diagnosed with severe atrioventricular valve regurgitation on pre-S2P echocardiogram, did not require extracorporeal membrane oxygenation before Norwood hospitalization discharge, and right ventricular ejection fraction=43.9% on the pre-S2P echocardiogram. Risk factor values, patient with multiple risk factors: Did not require extracorporeal membrane oxygenation at the end of the Norwood procedure, right ventricle-to-pulmonary artery conduit, received steroids, pre-Norwood tricuspid valve z score=0.4, no aberrant right subclavian artery, received aprotinin, site volume <30 Norwood procedures per year, cardiopulmonary bypass time=140 minutes, highest preNorwood lactate=1.9 mg/dL, deep hypothermic circulatory arrest time=60 minutes, post-Norwood neoaortic annular area z score=1.63, no pulmonary arterial stenosis, 1 postNorwood complication, diagnosed with failure to thrive, no diagnosis of severe atrioventricular valve regurgitation on pre-S2P echocardiogram, did not require extracorporeal membrane oxygenation before Norwood hospitalization discharge, and right ventricular ejection fraction=56.2% on pre-S2P echocardiogram. mize calculated 3-year transplant-free survival. Although the curve depicting this type of patient in the nomogram in Figure 4 flattened past 6 months, this is likely because of length-time bias. Our data certainly do not suggest that nonintervention in a deteriorating, high-risk infant would eventuate in higher survival. By 6 months, most of the highest-risk patients will have either died or undergone heart transplantation, thereby increasing the calculated survival estimates. We hypothesize that the patients undergoing early nonelective S2P are qualitatively different than those who undergo nonelective S2P late. Those undergoing S2P before 3 months may have pathology that was not amenable to surgical intervention (eg, ventricular dysfunction) versus those who undergo S2P after 6 months (eg, progressive cyanosis). We did not have data at a sufficiently granular level (oxygenation saturations, weights) to test this hypothesis.
Instead of recommending the avoidance of intervention in the ill post-Norwood patient who does not have pathology amenable to surgical intervention, prompt referral for heart transplantation may offer a greater chance at long-term survival. These patients may be better served by cardiac replacement, given the failure of S2P as a rescue that we have demonstrated. Two recent studies suggest that acceptable outcomes are achievable in infants undergoing single-ventricle palliation who require salvage heart transplantation. 39, 40 Further formal analysis of this treatment pathway versus high-risk progression to S2P is warranted.
Determinants of the Timing of S2P
This study addresses another knowledge gap in this field, the determinants of the timing of S2P. Patients with impaired ventricular function underwent S2P earlier, but not as soon as those with more acute anatomic issues such as shunt stenosis. Furthermore, a more complicated course after the Norwood also was associated with later progression to S2P, because a greater number of interstage operations was associated with a longer Norwood-S2P interval.
The intraoperative use of steroids during the Norwood was associated with the longest increase in the Norwood-S2P interval. The use of intraoperative steroids during the Norwood procedure is discussed in greater detail in the online-only Data Supplement Results. A significant association between intraoperative steroid use and death or heart transplantation was seen in multivariable analysis. Our results harmonize with a recent study of intraoperative steroid use during the Norwood in the SVR trial, in which intraoperative steroids were associated with greater hospital mortality in a multivariable logistic regression. 41 In a meta-analysis including 232 patients, intraoperative steroid use was not associated with significant reductions in morbidity or mortality in children undergoing cardiac surgery. 42 However, other published studies from the past decade present contradictory results. 43, 44 The exact mechanism by which intraoperative steroid use may lengthen the time between the Norwood and S2P remains unclear.
The association of intraoperative aprotinin with later S2P was both statistically significant (P=0.007) and reliable (80%). No secondary analysis of aprotinin use in the SVR trial has been performed. More detailed discussion can be found in the online-only Data Supplement Results. The drug was removed from the market in 2007 after several analyses suggested it was associated with greater rates of renal dysfunction in adults undergoing cardiac surgery on cardiopulmonary bypass. [44] [45] [46] [47] Evidence for its potential link with renal dysfunction in congenital heart surgery is mixed. Four single-center observational studies from the past decade examined the effect of aprotinin in children undergoing cardiac surgery and their findings were evenly split. No difference in mortality was found in patients who did or did not receive the drug. [48] [49] [50] [51] Our multivariable analysis did identify an association between aprotinin use and death or heart transplantation after the Norwood. If the incidence of renal dysfunction with aprotinin was greater in the SVR trial, then a longer intensive care unit or hospital length of stay may have delayed S2P.
Last, a site volume of 16 to 20 Norwood procedures per year was associated with a shorter Norwood-S2P interval. The SVR trial public data set includes center volume of Norwood procedures per year as a variable with 4 levels: ≤15 per year (17%), 16 to 20 per year (20%), 21 to 30 per year (32%), or ≥30 per year (31%). The median Norwood-S2P intervals did differ by site volume, 5.3 versus 4.2 versus 5.1 versus 4.8 months, respectively (P<0.0001). Although the Norwood-S2P interval was shortest at sites with a yearly volume of 16 to 20 Norwood procedures per year, transplant-free survival was lowest at the sites performing ≤15 Norwood procedures per year (59% versus 75% versus 79% versus 73%, respectively, P=0.006). Site and surgeon volume-outcomes relationships with the Norwood procedure have been well described. 52 The reasoning behind earlier S2P at these institutions is not immediately clear.
Limitations
This study is subject to several important limitations. Although it uses the SVR trial's publicly available data set, it is a secondary analysis and uses the data set to answer a question for which it was not originally designed. In reality, the timing of S2P is determined currently by multiple factors, including institutional protocols, surgeon preferences, and patient factors, such as oxygen saturation, weight, and pulmonary vascular resistance over time. In this data set, some potentially important variables were not present (eg, weight at S2P), had only 1 measurement recorded (eg, pulmonary vascular resistance on cardiac catheterization), or were represented using proxies, such as a diagnosis of failure to thrive. We were therefore unable to perform analyses using repeated measures of, eg, weight, oxygenation saturations, or pulmonary vascular resistance over time. The SVR trial data also lacked information regarding interstage home monitoring, which may also affect the timing of S2P based on specific clinical parameters. Finally, although the advantages of large, multicenter randomized controlled trials are obvious, they can also create an artificial environment to test a hypothesis. For example, nearly 90% of the patients included in the SVR trial were diagnosed with hypoplastic left heart syndrome. These strict enrollment criteria, while creating a homogenous patient population, also avoid the diagnostic and procedural complexity seen in the realworld clinical practice in patients undergoing the Norwood procedure.
From a methodologic perspective, the analysis is likely complicated by informative censoring, because the children who were rapidly transitioned to S2P may have also been likely to die soon after the Norwood. This risk of death likely affected the time to S2P and could bias the conditional survival analysis. Although multistate modeling may represent an attractive alternative approach, current available methods (such as Cox Markov models) are not inadequate for the complexity of this analysis, because the rates of transition between the Norwood to S2P and death/transplantation are both competing and time varying.
Clinical Implications
Several implications exist for the management of patients with few risk factors undergoing single-ventricle palliation. Defining the timing of S2P associated with greatest 3-year transplant-free survival allows for strategic planning after the initial Norwood procedure. At the time of discharge after the Norwood hospitalization, the adoption or modification of a formalized approach, in which S2P is explicitly planned and scheduled within 3 to 6 months of the Norwood, may lead to improved outcomes. Reducing variability in care across centers could lead to gains in survival through the staged management of single-ventricle palliation. However, flexibility and perspective are needed when managing individual infants given that the interstage period is rife with risk and may necessitate interval procedures, hospitalizations, and more that may affect the timing of S2P. Further refinement that enables individual, patientlevel predictions for optimal timing cannot be provided by this analysis, but merits additional investigation using a data source that can provide highly granular patient data, such as from the Congenital Heart Surgeons' Society Data Center.
In addition to allowing for operative planning, our findings, in particular, with regard to infants with multiple risk factors in whom single-ventricle palliation is likely to fail, can be used to counsel parents and ought to be incorporated into preoperative and prenatal consultations. The current practice of rapidly transitioning these patients out of Norwood circulation via early S2P resulted in especially poor transplant-free survival. This raises serious questions regarding this strategy. In these infants, early referral for heart transplantation ought to be considered, given the severely limited supply of organs for neonatal and infant transplantation. Further analyses are needed to weigh the potential benefits of early transplantation in these infants in light of the known scarcity of available organ donors in this age group.
CONCLUSIONS
In conclusion, in this analysis of the SVR trial public data set, the optimal timing for S2P is significantly influenced by patient characteristics and clinical status. For patients with few risk factors, scheduling S2P within 3 to 6 months of the Norwood at the time of discharge after the Norwood hospitalization may improve outcomes and reduce center-level variation in care. Survival in patients with greater risk factor burdens, especially those who require early S2P, will be severely adversely impacted. Progressing to S2P does not fundamentally change the risk profile of these patients. While earlier referral for heart transplantation may offer the greatest chance of long-term survival for high-risk patients, the supply of available organs will limit this approach. The detailed study of outcomes in heart transplantation in poor candidates for staged single-ventricle palliation and the development of methods to increase the number of available organs represent the next important steps in maximizing long-term survival in this precarious group of patients. Finally, the optimal timing did not differ by shunt type, regardless of risk profile.
